Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Equillium, Inc./ SCHEDULE 13G/A

SEC Filing · SCHEDULE 13G/A

Equillium, Inc.

EQNASDAQEQUITYCurrent

SEC Filing

Filed May 15, 2026Accepted May 15, 2026, 4:13 PM EDTCIK 1746466Accession 0001843384-26-000004
View company →Permanent SEC source ↗
Share

Company context

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways.

Current securities

EQNASDAQ · EQUITY · Current

Recent company filings

  1. 10-Q filingAug 13, 2026
  2. SCHEDULE 13G filingAug 13, 2026
  3. Results of Operations and Financial ConditionAug 13, 2026
  4. 4 filingMay 29, 2026
  5. 4 filingMay 29, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗